{
    "eu_accel_assess_g": "True",
    "eu_od_number": "__SCRAPER_NOT_FOUND__",
    "active_substance": "axicabtagene ciloleucel",
    "eu_aut_status": [
        {
            "value": "ACTIVE",
            "date": "2023-01-09"
        }
    ],
    "eu_brand_name_current": [
        {
            "value": "Yescarta",
            "date": "2023-01-09"
        }
    ],
    "assess_time_days_total": 334,
    "ema_od_number": "__SCRAPER_NOT_FOUND__",
    "eu_brand_name_initial": {
        "value": "Yescarta",
        "date": "2023-01-09"
    },
    "assess_time_days_active": "Not found",
    "eu_od_con": "__SCRAPER_NOT_FOUND__",
    "ema_number": "EMEA/H/C/004480",
    "atc_code": "__SCRAPER_NOT_FOUND__",
    "eu_nas": true,
    "ema_number_id": "4480",
    "assess_time_days_cstop": "Not found",
    "eu_od_date": "Date is left blank in source",
    "ema_procedure_start_initial": "2017-07-29",
    "chmp_opinion_date": "2018-06-28",
    "ema_number_certainty": "0.625",
    "ec_decision_time_days": 1656,
    "eu_od_pnumber": "__SCRAPER_NOT_FOUND__",
    "eu_aut_date": "2018-08-23",
    "ema_number_check": false,
    "eu_aut_type_initial": {
        "value": "__SCRAPER_NOT_FOUND__",
        "date": "2023-01-09"
    },
    "eu_mah_current": [
        {
            "value": "Kite Pharma EU B.V.",
            "date": "2023-01-09"
        }
    ],
    "ema_reexamination": "False",
    "eu_od_sponsor": [
        {
            "value": "__SCRAPER_NOT_FOUND__",
            "date": "2023-01-09"
        }
    ],
    "eu_aut_type_current": [
        {
            "value": "standard",
            "date": "2023-01-09"
        }
    ],
    "eu_mah_initial": {
        "value": "Kite Pharma EU B.V.",
        "date": "2023-01-09"
    },
    "eu_orphan_con_current": [
        {
            "value": [
                {
                    "pre": "o",
                    "id": "1393",
                    "eu_num": "EU/3/14/1393",
                    "indication": "Treatment of diffuse large B cell lymphoma",
                    "link_date": "2018-08-27"
                }
            ],
            "date": "2023-01-09"
        }
    ],
    "eu_od_comp_date": "Date is left blank in source",
    "eu_pnumber": "EU/1/18/1299",
    "eu_prime_initial": {
        "value": "True",
        "date": "2023-01-09"
    },
    "eu_legal_basis": [
        "article 8.3"
    ],
    "eu_referral": "False",
    "eu_indication_initial": {
        "value": "yescarta is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and primary mediastinal large b-cell lymphoma (pmbcl), after two or \n more lines of systemic therapy.\n",
        "date": "2023-01-09"
    },
    "aut_url": "https://ec.europa.eu/health/documents/community-register/2018/20180823142115/dec_142115_en.pdf",
    "eu_od_initial": {
        "value": "adopted",
        "date": "2023-01-09"
    },
    "eu_suspension": "False",
    "ema_omar_condition": [
        {
            "eu_od_number": "eu/3/14/1393",
            "eu_od_prevalence": "the prevalence of diffuse large b-cell lymphoma (hereinafter referred to as \u201cthe condition\u201d) was estimated to remain below 5 in 10,000 and was concluded to be 4.6 in 10,000 persons in the european union, at the time of the review of the designation criteria; ",
            "eu_od_alt_treatment": "significant_benefit",
            "eu_od_sig_benefit": "the sponsor has provided clinical data showing responses in patients with relapsed or refractory diffuse large b-cell lymphoma, which compare favourably to responses with existing treatments in historical controls.",
            "ema_report_date": "2018-08-23"
        },
        {
            "eu_od_number": "eu/3/15/1553",
            "eu_od_prevalence": "the prevalence of primary mediastinal large b-cell lymphoma (hereinafter referred to as \u201cthe condition\u201d) was estimated to remain below 5 in 10,000 and was concluded to be approximately 0.5 in 10,000 persons in the european union, at the time of the review of the designation criteria; ",
            "eu_od_alt_treatment": "significant_benefit",
            "eu_od_sig_benefit": "the sponsor has provided clinical data showing responses in patients with relapsed or refractory primary mediastinal large b-cell lymphoma, which compare favourably to responses with existing treatments in historical controls.",
            "ema_report_date": "2018-08-23"
        }
    ],
    "smpc_url": "https://ec.europa.eu/health/documents/community-register/2018/20180823142115/anx_142115_en.pdf",
    "ema_rapp": "jan mueller",
    "omar_url": "https://www.ema.europa.eu/documents/orphan-maintenance-report/yescarta-orphan-maintenance-assessment-report-initial-authorisation_en.pdf",
    "epar_url": "https://www.ema.europa.eu/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf",
    "eu_procedures_todo": [
        {
            "eu_referral": false,
            "eu_suspension": false
        }
    ],
    "eu_atmp": true,
    "ema_corapp": "claire beuneu",
    "odwar_url": "404_url_not_found",
    "orphan_status": "h",
    "eu_med_type": "small molecule"
}